MedCity News September 9, 2024
The weight loss results for the Terns Pharmaceuticals drug TERN-601 come from a four-week Phase 1 clinical trial. Terns is one of several companies developing oral GLP-1 obesity medications that could become alternatives to currently available injectable products from this drug class.
An experimental GLP-1 obesity drug from Terns Pharmaceuticals led to a 5.5% reduction in body weight in a small study, continuing to build its case as a potential oral alternative to currently available injectable obesity medicines. With these encouraging early data in hand, Terns now aims to see if the drug can replicate the results in a larger mid-stage clinical trial expected to begin next year.
The data announced Monday are from a multiple-ascending dose Phase 1 clinical...
Today's Sponsors
Today's Sponsor